JMP Securities Reaffirms “Market Outperform” Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “market outperform” rating reissued by research analysts at JMP Securities in a note issued to investors on Monday, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. JMP Securities’ target price indicates a potential upside of 464.97% from the stock’s previous close.

MRNS has been the topic of several other research reports. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Truist Financial restated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Finally, Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a report on Monday. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Marinus Pharmaceuticals Stock Performance

NASDAQ:MRNS opened at $1.77 on Monday. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The company has a 50-day moving average of $1.38 and a 200-day moving average of $2.78. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The firm has a market cap of $97.23 million, a price-to-earnings ratio of -0.67 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter last year, the firm posted ($0.61) EPS. Analysts forecast that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Trexquant Investment LP acquired a new position in Marinus Pharmaceuticals in the fourth quarter worth approximately $553,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth $1,146,000. Superstring Capital Management LP bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $5,027,000. Wellington Management Group LLP lifted its stake in shares of Marinus Pharmaceuticals by 54.8% in the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after purchasing an additional 85,455 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. bought a new stake in Marinus Pharmaceuticals in the first quarter worth $664,000. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.